DOP2023000165A - Anticuerpos de unión a cd3 - Google Patents
Anticuerpos de unión a cd3Info
- Publication number
- DOP2023000165A DOP2023000165A DO2023000165A DO2023000165A DOP2023000165A DO P2023000165 A DOP2023000165 A DO P2023000165A DO 2023000165 A DO2023000165 A DO 2023000165A DO 2023000165 A DO2023000165 A DO 2023000165A DO P2023000165 A DOP2023000165 A DO P2023000165A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- binding antibodies
- diagnosis
- treatment
- various diseases
- refers
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012642 immune effector Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención hace referencia a polipéptidos de unión al antígeno CD3 humano novedosos y su preparación y uso en el tratamiento y/o diagnóstico de diversas enfermedades, y también hace referencia a moléculas de anticuerpos biespecíficos capaces de activar células efectoras inmunitarias y su uso en el diagnóstico y/o tratamiento de diversas enfermedades.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662394360P | 2016-09-14 | 2016-09-14 | |
US201762491908P | 2017-04-28 | 2017-04-28 | |
PCT/US2017/038377 WO2018052503A1 (en) | 2016-09-14 | 2017-06-20 | Cd3 binding antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2023000165A true DOP2023000165A (es) | 2023-10-15 |
Family
ID=61619675
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2019000059A DOP2019000059A (es) | 2016-09-14 | 2019-03-13 | Anticuerpos de unión a cd3 |
DO2022000233A DOP2022000233A (es) | 2016-09-14 | 2022-10-27 | Anticuerpos de unión a cd3 |
DO2023000165A DOP2023000165A (es) | 2016-09-14 | 2023-08-24 | Anticuerpos de unión a cd3 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2019000059A DOP2019000059A (es) | 2016-09-14 | 2019-03-13 | Anticuerpos de unión a cd3 |
DO2022000233A DOP2022000233A (es) | 2016-09-14 | 2022-10-27 | Anticuerpos de unión a cd3 |
Country Status (31)
Country | Link |
---|---|
US (4) | US11505606B2 (es) |
EP (3) | EP3512549A4 (es) |
JP (6) | JP7030109B2 (es) |
KR (4) | KR20240044520A (es) |
CN (3) | CN117603353A (es) |
AU (2) | AU2017327723B2 (es) |
BR (2) | BR112019004873A2 (es) |
CA (1) | CA3036550A1 (es) |
CL (4) | CL2019000643A1 (es) |
CO (1) | CO2019003706A2 (es) |
CR (3) | CR20220578A (es) |
DK (1) | DK4050034T3 (es) |
DO (3) | DOP2019000059A (es) |
EC (1) | ECSP19026304A (es) |
ES (1) | ES2980623T3 (es) |
FI (1) | FI4050034T3 (es) |
HR (1) | HRP20240767T1 (es) |
HU (1) | HUE066651T2 (es) |
IL (3) | IL290517B1 (es) |
LT (1) | LT4050034T (es) |
MX (2) | MX2019002967A (es) |
PE (2) | PE20190976A1 (es) |
PH (1) | PH12019500545A1 (es) |
PL (1) | PL4050034T3 (es) |
PT (1) | PT4050034T (es) |
RS (1) | RS65595B1 (es) |
SA (2) | SA522431672B1 (es) |
SI (1) | SI4050034T1 (es) |
UA (1) | UA126384C2 (es) |
WO (1) | WO2018052503A1 (es) |
ZA (1) | ZA202203250B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3471773A4 (en) * | 2016-06-21 | 2020-07-08 | Teneobio, Inc. | ANTIBODIES BINDING CD3 |
PT4050034T (pt) * | 2016-09-14 | 2024-05-27 | Teneoone Inc | Anticorpos de ligação a cd3 |
IL300729A (en) | 2016-12-21 | 2023-04-01 | Teneobio Inc | Anti-BCMA antibodies containing only heavy chains |
WO2018237006A1 (en) | 2017-06-20 | 2018-12-27 | Teneoone, Inc. | ANTIBODIES ONLY TO HEAVY ANTI-BCMA CHAINS |
IL271194B2 (en) | 2017-06-20 | 2024-10-01 | Teneobio Inc | Anti-BCMA antibodies containing only heavy chains |
WO2019126756A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
SG11202006042SA (en) * | 2017-12-27 | 2020-07-29 | Teneobio Inc | Cd3-delta/epsilon heterodimer specific antibodies |
PE20210132A1 (es) | 2018-05-24 | 2021-01-19 | Janssen Biotech Inc | Anticuerpos anti-cd3 y usos de estos |
TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAx抗-CD3抗體及其用途 |
SG11202011597RA (en) | 2018-07-20 | 2020-12-30 | Teneobio Inc | Heavy chain antibodies binding to cd19 |
US10867104B2 (en) * | 2018-08-31 | 2020-12-15 | Taiwan Semiconductor Manufacturing Company Ltd. | Isolation circuit between power domains |
JP2022505445A (ja) | 2018-10-26 | 2022-01-14 | テネオバイオ, インコーポレイテッド | Cd38に結合する重鎖抗体 |
CN113710707B (zh) | 2019-04-05 | 2024-05-31 | 特尼奥生物股份有限公司 | 结合于psma的重链抗体 |
MX2021015337A (es) | 2019-06-14 | 2022-01-18 | Teneobio Inc | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3. |
WO2021022304A2 (en) * | 2019-07-30 | 2021-02-04 | Qlsf Biotherapeutics, Inc. | MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε |
CN112574308A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 靶向bcma的抗体、双特异性抗体及其用途 |
MX2022007613A (es) | 2019-12-18 | 2022-07-19 | Teneofour Inc | Union de anticuerpos de cadena pesada a cd38. |
PE20230431A1 (es) | 2020-04-29 | 2023-03-08 | Teneobio Inc | Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas |
WO2021222578A1 (en) | 2020-04-29 | 2021-11-04 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
EP4142791A1 (en) | 2020-04-29 | 2023-03-08 | TeneoOne, Inc. | Methods of treating multiple myeloma |
MX2022016342A (es) | 2020-06-30 | 2023-01-24 | Teneobio Inc | Union de anticuerpos multiespecificos a bcma. |
JP2023542257A (ja) | 2020-09-16 | 2023-10-05 | アムジェン インコーポレイテッド | 癌の治療のために二重特異性t細胞誘導分子の治療用量を投与する方法 |
TW202233684A (zh) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
CN117500835A (zh) | 2021-02-25 | 2024-02-02 | 特尼奥生物股份有限公司 | 抗psma抗体及car-t结构 |
JP2024508808A (ja) | 2021-02-26 | 2024-02-28 | テネオバイオ, インコーポレイテッド | 抗muc1-c抗体及びcar-t構造 |
TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗il-2r抗體及使用方法 |
AU2022255709A1 (en) | 2021-04-06 | 2023-09-28 | Teneobio, Inc. | Anti-cd19 antibodies and car-t structures |
PE20240656A1 (es) | 2021-04-16 | 2024-04-04 | Teneobio Inc | Anticuerpos anti-cd20 y estructuras car-t |
WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
KR20240021289A (ko) * | 2021-06-24 | 2024-02-16 | 엑사이트 바이오파마 리미티드 | Bcma 및 cd3에 결합하는 이중특이성 항체 및 그 제조 방법과 응용 |
WO2023288191A1 (en) * | 2021-07-13 | 2023-01-19 | University Of Washington | Multiple de novo designed protein binding proteins |
WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
JP2024531944A (ja) | 2021-08-09 | 2024-09-03 | ハーバー バイオメッド(シャンハイ)カンパニー リミテッド | Cldn18.2標的化抗体、二重特異性抗体、及びそれらの使用 |
WO2023064876A1 (en) | 2021-10-14 | 2023-04-20 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
WO2024026358A1 (en) | 2022-07-27 | 2024-02-01 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
WO2024178056A1 (en) | 2023-02-21 | 2024-08-29 | Teneobio, Inc. | C-kit binding proteins, chimeric antigen receptors, and uses thereof |
KR20240139569A (ko) * | 2023-03-13 | 2024-09-23 | 머스트바이오 주식회사 | 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체 |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
US5968509A (en) | 1990-10-05 | 1999-10-19 | Btp International Limited | Antibodies with binding affinity for the CD3 antigen |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6037453A (en) * | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
PT1642972E (pt) | 1999-01-07 | 2010-04-07 | Zymogenetics Inc | Utilizações terapêuticas de receptores solúveis br43x2 |
IL148089A0 (en) | 1999-08-17 | 2002-09-12 | Biogen Inc | Baff receptor (bcma), an immunorgulatory agent |
WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
DK2857516T3 (en) | 2000-04-11 | 2017-08-07 | Genentech Inc | Multivalent antibodies and uses thereof |
AU2001261557B2 (en) | 2000-05-12 | 2005-06-30 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
WO2002059264A2 (en) * | 2000-12-29 | 2002-08-01 | Bio-Technology General Corp. | Specific human antibodies for selective cancer therapy |
AU2002238052A1 (en) | 2001-02-20 | 2002-09-04 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
CN1195779C (zh) | 2001-05-24 | 2005-04-06 | 中国科学院遗传与发育生物学研究所 | 抗人卵巢癌抗人cd3双特异性抗体 |
GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
US7575893B2 (en) | 2003-01-23 | 2009-08-18 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
EP1629012B1 (en) | 2003-05-31 | 2018-11-28 | Amgen Research (Munich) GmbH | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
US7919089B2 (en) | 2003-05-31 | 2011-04-05 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody for EpCAM |
AU2004283850C1 (en) | 2003-10-16 | 2011-11-03 | Amgen Research (Munich) Gmbh | Multispecific deimmunized CD3-binders |
EP2865687A1 (en) * | 2003-12-10 | 2015-04-29 | E. R. Squibb & Sons, L.L.C. | IP-10 antibodies and their uses |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
BRPI0607203A2 (pt) | 2005-02-18 | 2009-08-25 | Medarex Inc | anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
JP2009507838A (ja) | 2005-09-12 | 2009-02-26 | ノビミューン エスアー | 抗cd3抗体製剤 |
EP3178850B1 (en) | 2005-10-11 | 2021-01-13 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
WO2007042289A2 (en) * | 2005-10-11 | 2007-04-19 | Ablynx N.V. | Nanobodies™ and polypeptides against egfr and igf-ir |
WO2007055916A2 (en) | 2005-11-07 | 2007-05-18 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
JP6088723B2 (ja) | 2005-11-23 | 2017-03-01 | ジェネンテック, インコーポレイテッド | B細胞アッセイに関する組成物及び方法。 |
CN101426815A (zh) | 2005-12-06 | 2009-05-06 | 杜门蒂斯有限公司 | 具有表皮生长因子受体和/或血管内皮生长因子结合特异性的配体及其使用方法 |
EP3456351A1 (en) | 2006-04-05 | 2019-03-20 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
US7862813B2 (en) | 2006-07-29 | 2011-01-04 | Bjork Jr Robert Lamar | Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug |
EA200970250A1 (ru) * | 2006-09-05 | 2010-02-26 | Медарекс, Инк. | Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения |
KR101589759B1 (ko) | 2007-04-03 | 2016-01-29 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 cd3―입실론 결합 도메인 |
WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
AU2008259939B2 (en) | 2007-06-01 | 2014-03-13 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
JP5739326B2 (ja) | 2008-04-25 | 2015-06-24 | ザイモジェネティクス, インコーポレイテッド | B細胞上でのbcmaタンパク発現レベル及び診断法における使用 |
US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
EP2370467B1 (en) | 2008-10-01 | 2016-09-07 | Amgen Research (Munich) GmbH | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
PT2352763E (pt) | 2008-10-01 | 2016-06-02 | Amgen Res (Munich) Gmbh | Anticorpos biespecíficos de cadeia única com especificidade para antigénios-alvo com elevado peso molecular |
PT2356153T (pt) | 2008-10-01 | 2016-07-15 | Amgen Res (Munich) Gmbh | Anticorpo biespecífico, de cadeia única, amepxcd3, específico interespécies |
US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
PL2406284T3 (pl) | 2009-03-10 | 2017-09-29 | Biogen Ma Inc. | Przeciwciała anty-bcma |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
RS55315B2 (sr) * | 2010-02-08 | 2020-08-31 | Regeneron Pharma | Miš sa zajedničkim lakim lancem |
TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
EP2640750A1 (en) | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Agents and methods for treating diseases that correlate with bcma expression |
JP2014515598A (ja) | 2011-03-10 | 2014-07-03 | エイチシーオー アンティボディ, インク. | 二重特異性三鎖抗体様分子 |
WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
PT3415531T (pt) | 2011-05-27 | 2023-09-12 | Glaxo Group Ltd | Proteínas de ligação a bcma (cd269/tnfrsf17 |
TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
SG11201406346SA (en) | 2012-04-20 | 2014-11-27 | Emergent Product Dev Seattle | Cd3 binding polypeptides |
BR112014032916A2 (pt) * | 2012-06-28 | 2017-08-01 | Pfizer | anticorpos anti-fármacos e usos destes para o monitoramento de fármaco |
US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
US10002206B2 (en) | 2012-10-26 | 2018-06-19 | Saturn Licensing Llc | Information processing device and information processing method |
AU2013340799B2 (en) | 2012-11-01 | 2018-08-09 | Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) | An antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
WO2014093908A2 (en) | 2012-12-14 | 2014-06-19 | Omt, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
EP2762496A1 (en) * | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
JP2016507523A (ja) | 2013-02-05 | 2016-03-10 | エンクマフ アーゲー | CD3εおよびBCMAに対する二重特異的抗体 |
EP3063173B1 (en) | 2013-10-31 | 2020-07-29 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
AU2014343636A1 (en) | 2013-11-04 | 2016-06-02 | Glenmark Pharmaceuticals S.A. | Production of T cell retargeting hetero-dimeric immunoglobulins |
WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
US10106623B2 (en) | 2014-02-12 | 2018-10-23 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
TWI754319B (zh) * | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
US9822186B2 (en) | 2014-03-28 | 2017-11-21 | Xencor, Inc. | Bispecific antibodies that bind to CD38 and CD3 |
MX2017001011A (es) * | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
AU2014409276A1 (en) | 2014-10-22 | 2017-04-06 | Crescendo Biologics Limited | Transgenic mice |
EP3023437A1 (en) * | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
SI3221357T1 (sl) * | 2014-11-20 | 2020-09-30 | F. Hoffmann-La Roche Ag | Pogoste lahke verige in načini uporabe |
DK3628687T3 (da) | 2014-12-12 | 2021-10-18 | 2Seventy Bio Inc | Kimære bcma-antigenreceptorer |
CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
GB201500461D0 (en) | 2015-01-12 | 2015-02-25 | Cresendo Biolog Ltd | Therapeutic molecules |
EP3056512A1 (en) * | 2015-02-10 | 2016-08-17 | Medizinische Universität Wien | Antibody construct |
CN106211261B (zh) | 2015-04-10 | 2020-10-16 | 中兴通讯股份有限公司 | 信息处理方法及通信节点 |
EP4219561A3 (en) | 2015-05-20 | 2023-11-08 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies |
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
CN108350076B (zh) | 2015-08-17 | 2022-06-07 | 詹森药业有限公司 | 抗-bcma抗体,结合bcma和cd3的双特异性抗原结合分子及其用途 |
JP2019503167A (ja) | 2015-11-10 | 2019-02-07 | ユニバーシティ・メディカル・センター・ハンブルク−エッペンドルフUniversity Medical Center Hamburg − Eppendorf | Cd38に対する抗原結合性ポリペプチド |
EP3471773A4 (en) | 2016-06-21 | 2020-07-08 | Teneobio, Inc. | ANTIBODIES BINDING CD3 |
US20190225671A1 (en) | 2016-08-24 | 2019-07-25 | Teneobio, Inc. | Transgenic non-human animals producing modified heavy chain-only antibodies |
PT4050034T (pt) * | 2016-09-14 | 2024-05-27 | Teneoone Inc | Anticorpos de ligação a cd3 |
IL300729A (en) | 2016-12-21 | 2023-04-01 | Teneobio Inc | Anti-BCMA antibodies containing only heavy chains |
WO2018237006A1 (en) | 2017-06-20 | 2018-12-27 | Teneoone, Inc. | ANTIBODIES ONLY TO HEAVY ANTI-BCMA CHAINS |
IL271194B2 (en) | 2017-06-20 | 2024-10-01 | Teneobio Inc | Anti-BCMA antibodies containing only heavy chains |
WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
ES2928296T3 (es) | 2017-06-30 | 2022-11-16 | Us Health | Receptores de antígenos quiméricos anti-antígenos de maduración de linfocitos B con dominios humanos |
WO2019126756A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
SG11202006042SA (en) * | 2017-12-27 | 2020-07-29 | Teneobio Inc | Cd3-delta/epsilon heterodimer specific antibodies |
EP3801551A4 (en) * | 2018-05-24 | 2022-04-06 | Ayala Pharmaceuticals Inc. | COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USE THEREOF |
SG11202011597RA (en) | 2018-07-20 | 2020-12-30 | Teneobio Inc | Heavy chain antibodies binding to cd19 |
US20210355215A1 (en) | 2018-09-21 | 2021-11-18 | Teneobio, Inc. | Methods for purifying heterodimeric, multispecific antibodies |
JP2022505445A (ja) | 2018-10-26 | 2022-01-14 | テネオバイオ, インコーポレイテッド | Cd38に結合する重鎖抗体 |
CN113710707B (zh) | 2019-04-05 | 2024-05-31 | 特尼奥生物股份有限公司 | 结合于psma的重链抗体 |
MX2021015337A (es) * | 2019-06-14 | 2022-01-18 | Teneobio Inc | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3. |
WO2021222578A1 (en) | 2020-04-29 | 2021-11-04 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
PE20230431A1 (es) | 2020-04-29 | 2023-03-08 | Teneobio Inc | Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas |
EP4142791A1 (en) | 2020-04-29 | 2023-03-08 | TeneoOne, Inc. | Methods of treating multiple myeloma |
US20220235380A1 (en) * | 2021-01-26 | 2022-07-28 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
WO2023064876A1 (en) * | 2021-10-14 | 2023-04-20 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
-
2017
- 2017-06-20 PT PT221592785T patent/PT4050034T/pt unknown
- 2017-06-20 FI FIEP22159278.5T patent/FI4050034T3/fi active
- 2017-06-20 BR BR112019004873A patent/BR112019004873A2/pt unknown
- 2017-06-20 BR BR122022002481A patent/BR122022002481A8/pt unknown
- 2017-06-20 DK DK22159278.5T patent/DK4050034T3/da active
- 2017-06-20 IL IL290517A patent/IL290517B1/en unknown
- 2017-06-20 PE PE2019000520A patent/PE20190976A1/es unknown
- 2017-06-20 LT LTEP22159278.5T patent/LT4050034T/lt unknown
- 2017-06-20 EP EP17851217.4A patent/EP3512549A4/en active Pending
- 2017-06-20 SI SI201731524T patent/SI4050034T1/sl unknown
- 2017-06-20 HR HRP20240767TT patent/HRP20240767T1/hr unknown
- 2017-06-20 UA UAA201903677A patent/UA126384C2/uk unknown
- 2017-06-20 RS RS20240647A patent/RS65595B1/sr unknown
- 2017-06-20 EP EP22159278.5A patent/EP4050034B1/en active Active
- 2017-06-20 CR CR20220578A patent/CR20220578A/es unknown
- 2017-06-20 MX MX2019002967A patent/MX2019002967A/es unknown
- 2017-06-20 IL IL313895A patent/IL313895A/en unknown
- 2017-06-20 AU AU2017327723A patent/AU2017327723B2/en active Active
- 2017-06-20 KR KR1020247009294A patent/KR20240044520A/ko active Search and Examination
- 2017-06-20 CN CN202311092843.4A patent/CN117603353A/zh active Pending
- 2017-06-20 KR KR1020197010099A patent/KR102505681B1/ko active IP Right Grant
- 2017-06-20 PL PL22159278.5T patent/PL4050034T3/pl unknown
- 2017-06-20 CR CR20190198A patent/CR20190198A/es unknown
- 2017-06-20 JP JP2019514099A patent/JP7030109B2/ja active Active
- 2017-06-20 CA CA3036550A patent/CA3036550A1/en active Pending
- 2017-06-20 ES ES22159278T patent/ES2980623T3/es active Active
- 2017-06-20 KR KR1020237007421A patent/KR20230035706A/ko not_active Application Discontinuation
- 2017-06-20 CN CN201780062822.4A patent/CN109843325B/zh active Active
- 2017-06-20 EP EP24172651.2A patent/EP4417263A2/en active Pending
- 2017-06-20 KR KR1020227006672A patent/KR102507537B1/ko active Application Filing
- 2017-06-20 US US16/332,665 patent/US11505606B2/en active Active
- 2017-06-20 IL IL265321A patent/IL265321B2/en unknown
- 2017-06-20 CN CN202210150122.3A patent/CN114395048A/zh active Pending
- 2017-06-20 WO PCT/US2017/038377 patent/WO2018052503A1/en active Application Filing
- 2017-06-20 CR CR20220408A patent/CR20220408A/es unknown
- 2017-06-20 HU HUE22159278A patent/HUE066651T2/hu unknown
- 2017-06-20 PE PE2024000894A patent/PE20241349A1/es unknown
-
2019
- 2019-03-13 MX MX2022002018A patent/MX2022002018A/es unknown
- 2019-03-13 CL CL2019000643A patent/CL2019000643A1/es unknown
- 2019-03-13 SA SA522431672A patent/SA522431672B1/ar unknown
- 2019-03-13 DO DO2019000059A patent/DOP2019000059A/es unknown
- 2019-03-13 SA SA523442262A patent/SA523442262B1/ar unknown
- 2019-03-13 PH PH12019500545A patent/PH12019500545A1/en unknown
- 2019-04-12 CO CONC2019/0003706A patent/CO2019003706A2/es unknown
- 2019-04-12 EC ECSENADI201926304A patent/ECSP19026304A/es unknown
-
2021
- 2021-10-01 US US17/492,444 patent/US11421027B2/en active Active
- 2021-12-09 CL CL2021003290A patent/CL2021003290A1/es unknown
- 2021-12-09 CL CL2021003289A patent/CL2021003289A1/es unknown
-
2022
- 2022-01-04 JP JP2022000116A patent/JP7321303B2/ja active Active
- 2022-01-04 JP JP2022000115A patent/JP7431868B2/ja active Active
- 2022-02-24 AU AU2022201278A patent/AU2022201278B2/en active Active
- 2022-03-18 ZA ZA2022/03250A patent/ZA202203250B/en unknown
- 2022-08-19 US US17/821,143 patent/US20230082151A1/en active Pending
- 2022-10-03 US US17/937,750 patent/US20230272075A1/en active Pending
- 2022-10-27 DO DO2022000233A patent/DOP2022000233A/es unknown
- 2022-12-26 CL CL2022003769A patent/CL2022003769A1/es unknown
-
2023
- 2023-07-25 JP JP2023120345A patent/JP2023156342A/ja active Pending
- 2023-08-24 DO DO2023000165A patent/DOP2023000165A/es unknown
- 2023-11-08 JP JP2023190748A patent/JP7521728B2/ja active Active
- 2023-11-08 JP JP2023190749A patent/JP7521729B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2023000165A (es) | Anticuerpos de unión a cd3 | |
MX2024005027A (es) | Anticuerpos de union a cd3. | |
MX2020006715A (es) | Anticuerpos especificos del heterodimero de cd3-delta/epsilon. | |
CL2020002305A1 (es) | Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1 | |
PH12018501882A1 (en) | Binding proteins and methods of use thereof | |
UY37127A (es) | Moléculas de unión a ror1, y métodos de uso de las mismas | |
BR112018074453A2 (pt) | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral | |
AR092818A1 (es) | Anticuerpo tau humanizado | |
CY1124153T1 (el) | Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127 | |
AR106754A1 (es) | Proteínas de unión a la proteína de muerte celular programada (pd1) y/o gen de activación de linfocitos 3 (lag3) | |
ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
BR112016011025A2 (pt) | polipeptídeos anticorpo e seus usos | |
BR112018068678A2 (pt) | anticorpos anti-mica | |
PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
WO2018111670A3 (en) | Antibodies to human alpha-synuclein | |
EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
DOP2012000232A (es) | Proteínas de unión a antigeno especificas para el componente amiloide serico p | |
CY1123519T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß | |
UY37082A (es) | Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv | |
BR112018006820A2 (pt) | anticorpos anti-psa (5a10) humanizados | |
TH136515A (th) | แอนติบอดีของคนที่มีสัมพรรคภาพสูงต่อแองจิโอโพอิทิน-2-ของคน | |
TH136515B (th) | แอนติบอดีของคนที่มีสัมพรรคภาพสูงต่อแองจิโอโพอิทิน-2-ของคน |